SRA International, Inc. to Acquire Constella Group, LLC
June 20 2007 - 9:57AM
PR Newswire (US)
FAIRFAX, Va., June 20 /PRNewswire-FirstCall/ -- SRA International,
Inc. (NYSE:SRX), a leading provider of technology and strategic
consulting services and solutions to federal government
organizations, today announced the signing of a definitive
agreement to acquire Constella Group, LLC, a privately-held
provider of global health consulting services. Headquartered in
Durham, NC, Constella employs more than 1,500 professionals
organized by three interrelated service offerings: domestic health
sciences, international health development and global drug
development. The domestic health sciences business provides
research, technology, communications and strategy support to U.S.
government agencies charged with protecting and advancing the
health of their constituents. Constella's international health
development business helps emerging nations across the world create
and implement health policy, primarily through contracts with the
governments of the U.S. and the United Kingdom. The global drug
development business provides blue-chip pharmaceutical,
biotechnology and medical device firms with the strategic insight
and services needed to take a drug, biologic or device through the
development process from concept to market. The company's
combination of capabilities, domain expertise and geographic reach
enable it to offer differentiated solutions to address the world's
most complex health issues. Constella acquired two companies during
calendar year 2006. Excluding pre-acquisition revenue for those two
companies, Constella revenue for calendar year 2006 was
approximately $169 million. SRA President and CEO Stan Sloane said,
"Constella's deep domain expertise, combined with the capabilities
of our existing health business, will offer a comprehensive
solution in the global health marketplace. We're delighted to
welcome Constella's employees and customers to SRA. They will form
the foundation of a new health business unit to be led by Don
Holzworth, which will bring even greater focus to this growing
market in the future." Commenting on the sale, Constella's founder
and CEO Donald Holzworth added, "We've worked with SRA for many
years and have high respect for their management and culture. Our
companies were both built on a powerful vision, and we look forward
to significant opportunities for growth and expansion together."
SRA Executive Vice President and Chief Financial Officer Stephen
Hughes stated, "Constella's health market credentials address a key
element of our long-term strategy. We expect this transaction to be
accretive to earnings in Fiscal Year 2008, with significant cash
tax benefits. We believe the strength and stability of our cash
flows provide ample borrowing capacity to make further acquisitions
in the near term." Completion of the transaction is subject to
customary closing conditions and the Hart-Scott-Rodino waiting
period, and closing is expected within approximately one month.
William Blair & Company, LLC acted as the exclusive advisor to
Constella Group in this transaction. About SRA International, Inc.
SRA is a leading provider of technology and strategic consulting
services and solutions - including systems design, development, and
integration; and outsourcing and managed services - to clients in
national security, civil government, and health care and public
health markets. The Company also delivers business solutions for
contingency and disaster response planning, information assurance,
business intelligence, environmental strategies, enterprise
architecture, infrastructure management, and wireless integration.
FORTUNE(R) magazine has chosen SRA as one of the "100 Best
Companies to Work For" for eight consecutive years. The Company's
5,200 employees serve clients from its headquarters in Fairfax,
Virginia, and offices across the country. For additional
information on SRA, please visit http://www.sra.com/ . Any
statements in this press release about future expectations, plans,
and prospects for SRA, including statements about the estimated
value of the contract and work to be performed, and other
statements containing the words "estimates," "believes,"
"anticipates," "plans," "expects," "will," and similar expressions,
including those about our expectations as to timing of the closing,
the accretiveness of the transaction to our earnings, and our
borrowing capacity, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
such forward-looking statements as a result of the factors
discussed in our latest quarterly report on Form 10-Q filed with
the Securities and Exchange Commission on May 3, 2007. In addition,
the forward-looking statements included in this press release
represent our views as of June 20, 2007. We anticipate that
subsequent events and developments will cause our views to change.
However, while we may elect to update these forward-looking
statements at some point in the future, we specifically disclaim
any obligation to do so. These forward-looking statements should
not be relied upon as representing our views as of any date
subsequent to June 20, 2007. DATASOURCE: SRA International, Inc.
CONTACT: David Keffer, Director, Investor Relations,
+1-703-502-7731, , or Stephen Hughes, Executive VP and CFO,
+1-703-227-8350, , both of SRA International, Inc. Web site:
http://www.sra.com/
Copyright
Sra (NYSE:SRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sra (NYSE:SRX)
Historical Stock Chart
From Jul 2023 to Jul 2024